semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-72.0,  Type 1 Diabetes type 1 diabetes, stabile statin drug use, HbA1c <9%  liver, kidney and thyroid dysfunction, severe diabetic proteinuria, gastroparesis, unstable CAD, unstable inflammatory gastrointestinal disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Diabetes Mellitus, Type 1 aged between 18 and 45 years with diagnosed Type 1 diabetes mellitus (with or without complications or peripheric vascular micro-angiopathy) having a negative myocardial ischemic test (exercise echocardiography) in the previous month  Known or suspected coronary artery disease atrial fibrillation hypertension moderate to severe valvular disease sequelae of myocardial infarction secondary or primary cardiomyopathy myocardial conduction abnormalities pregnancy or breastfeeding
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Type 1 Diabetes diabetes duration > 5 years HbA1c < or = 7.2% CSII treated for > 3 months Capable of being moderately, physically active for 20 minutes  symptoms of diabetic late complications except simplex retinopathy pregnancy or nursing
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  it is a Group of Metabolic Diseases in Which a Person Has High Blood Sugar, Either Because the Body Does Not Produce Enough Insulin, or Because Cells do Not Respond to the Insulin That is Produced. Male or Female 2. Above 18-65 Years of old 3. Known diabetic patients with HbA1c>8.0% 4. People who provide signed informed consent -  Pregnancy 2. Diabetic patients with HbA1c <8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Severe Hypertriglyceridemia Men and women, ages 18-79 Fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL Provide written informed consent and authorization for protected health information disclosure  Women who are pregnant or lactating, or planning to become pregnant Use of non-statin lipid-altering drugs which cannot be stopped or other supplements with potential lipid-altering effects History of pancreatitis History of bariatric surgery or currently on weight loss drugs or in weight loss programs Treatment with any agent that may affect lipid levels or hepatic function Consumption of more than 3 alcoholic beverages per day History of cancer within last 2 years Participation in another clinical trial involving an investigational agent in the last 30 days Other parameters will be assessed at the study center to ensure for this study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 50.0-70.0,  Type 2 Diabetes Both genders age 50-70 years Type two diabetes with at least two-year history of disease and without insulin treatment in the first two years after diagnosis Negative medical history for documented previous cardiovascular events or macrovascular complications Written consent to participate Presence of at least 2 of the following risk factors LDL cholesterol > 130 mg/dL (regardless of treatment) Triglycerides > 200 mg/dL HDL cholesterol < 35 (males) or 45 (females) mg/dL Blood pressure > 140/90 mmHg  Age below 50 or above 70 years Type 1 diabetes, diagnosis before 40 years of age, known presence of auto-antibodies or insulin requirement in the first 2 years of disease Chronic kidney failure (plasma creatinine > 2 mg/dL) Significant liver damage (AST and/or ALT > 2 times the upper limits of normality) History of previous cardiovascular events Active neoplasms or any concomitant disease limiting life expectancy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ischemic Stroke Transient Ischemic Attack Atherosclerotic Stenosis • Recent (less than 3 months) ischemic stroke As soon as possible after the event, once the neurologic deficit is stabilized (investigator judgment) These ischemic strokes TIA with ischemic lesion documented by CT or MRI • Or recent TIA (less than 15 days) without documentation of ischemic lesion on CT/MR imaging Must be limb weakness or aphasia lasting more than 10 min • And documented atherosclerotic stenosis In carotid artery (investigator judgment) (based on the results of Duplex echography, CTA, MRA or X ray angiography) Or in the aortic arch (investigator judgment) (based on TEE or CTA) Or in other brain artery: vertebral, basilar or other intracranial artery (based on CTA, MRA, XRA) Or in coronary arteries (past history of acute coronary syndrome, coronary revascularization or positive coronary angiography) • And  • Ischemic stroke/TIA du to arterial dissection (investigator judgment) Cardiac source of embolism (e.g., mitral stenosis, endomyocardial fibrosis) without documented atherosclerotic stenosis : a patient with atrial fibrillation or a past history of recent myocardial infarction or calcified aortic stenosis can be randomized if he otherwise fulfils • Symptomatic hemorrhagic stroke Presence of microbleeds on gradient echo imaging (T2*) is not an Hemorrhagic transformation of an ischemic stroke is not an Uncontrolled hypertension (investigator judgment) LDL-C <100 mg/dL or patients for whom treatment intensification is impossible F/U impossible or bad observance anticipated Co-morbid condition that may interfere with the F/U or with the evaluation of primary endpoint Participation to another clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 14.0-22.0,  Cystic Fibrosis Inflammatory Bowel Disease Type 1 Diabetes Chronic Disease Management ages 14 years have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months have access to the internet speak English has a parent that speaks English or Spanish (if primary participant is under 18) willingness to attend assessment visits  pregnant or have children have a history of substance abuse or other psychiatric disorder that would impair compliance with study protocol
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-34.0,  Type 2 Diabetes Mellitus You are one of a sibling pair with the same mother and father, and your mother had diabetes (gestational or type 2) while she was pregnant with the younger sibling but not the older sibling Your sibling is willing to participate in the study You are between the ages of 20 and 34 years (inclusive) Your body mass index is between 20 and 29 Kg/m2 inclusive (this is a number calculated for your height and weight and indicates that you are either normal weight or overweight, but not obese) You are healthy as assessed by medical history and standard physical examination You are weight stable (your body weight has not changed .6.5 lbs over the last 3 months) You do not smoke You provide written informed consent to participate in the study You are willing to stay overnight one time at the Pennington Center You have low physical activity (< 100 min of exercise per week)  You were born prematurely (<37 weeks of pregnancy) You are currently taking medication that may influence your body weight or metabolism You have heart disease, lung disease, liver disease, blood disease, kidney disease, type 1 or 2 diabetes, or any other disease that in the opinion of the doctor might make you ineligible
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Type 2 Diabetes Mellitus Understanding of the study procedures and agreement to participate in the study by giving written informed consent Males and females age 20 to 75 years, inclusive HbA1c ≥7.5% and ≤10% BMI ≤45 kg/m2 FPG ≤270 mg/dL Diagnosis of type 2 diabetes mellitus for ≥6 months On a stable regimen of oral anti-diabetic medications for ≥3 months Willingness to maintain stable diet and exercise throughout the study Willingness to maintain current doses/regimens of vitamins and dietary supplements throughout the study Female patients of childbearing potential and female partners of male patients must be willing to use adequate contraception during the study. All females of childbearing potential must have a negative urine pregnancy test at screening  History of type 1 diabetes and/or history of ketoacidosis History of diabetic neuropathy resulting in significant functional impairment and/or requiring active medical or surgical management, including chronic pain syndromes, gastroparesis, skin ulceration, or amputation History of long-term therapy with insulin (>30 days) within 1 year of screening Pregnancy or lactation Current treatment with any of the following medications within 2 months of screening Anti inflammatory drugs, including chronic daily use of systemic corticosteroids (aspirin ≤325 mg per day is allowed) IL-1 modulators: anakinra and rilonacept Immunosuppressive drugs: TNF inhibitors and IL-6 monoclonal antibody History of severe hypoglycemic episodes within 6 months of screening Hypersensitivity to AC-201 or anthraquinone derivatives
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypercholesterolemia Participants with primary hypercholesterolemia receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period or drug naive participants if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy OR Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period and likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit  LDL-C < 100 mg/dL (< 2.59 mmol/L) After the run-in period on atorvastatin (10 mg, 20 mg, or 40 mg) for participants receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the screening, or drug naive participant OR At the first visit for participants who were being treated with stable dose of atorvastatin (10 mg, 20 mg, or 40 mg) for at least 6 weeks prior to screening 2. Participants not previously instructed on a cholesterol-lowering diet 3. Participants with type 1 diabetes 4. Participants with type 2 diabetes treated with insulin 5. Participants with type 2 diabetes and with an glycated hemoglobin (HbA1c) ≥ 8.5% at screening visit (considered poorly controlled) 6. Laboratory findings measured before randomization Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit Positive serum or urine pregnancy test in females of childbearing potential 7. Pregnant or breast-feeding women 8. Women of childbearing potential with no effective contraceptive method The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Cardiomyopathy more than 18 years old patient type 2 diabetes affects taken care more than 5 years to Timone Hospital patient with a diabetic cardiomyopathy informed and consented  less than 18 years Pregnant woman patient type 1 diabetes affects patient presents a cardiomyopathy mixed (no diabetic) patients presents an arrhythmia ventriculaire or above ventriculaire Unstable hémodynamique patients
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 1 Diabetes Clinical diagnosis of type 1 diabetes for at least one year On insulin pump therapy for at least 3 months HbA1c ≤ 10%  Clinically significant nephropathy, neuropathy or retinopathy Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery A recent injury to body or limb, muscular disorder, use of any medication or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol Pregnancy Severe hypoglycemic episode within two weeks of screening Current use of glucocorticoid medication (by any route of administration except low dose stable inhaled) Known or suspected allergy to the trial products or meal contents Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator Anticipating a significant change in exercise regimen between admissions (i.e. starting or stopping an organized sport) Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus  Type 2 Diabetes Mellitus